137.STU Aldeyra Therapeutics Inc.
- Market cap
- -
- P/E
- -
- P/B
- 0.89x
- ROE
- -47.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 137.STU undervalued?
Graham numberThe Graham number of Aldeyra Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aldeyra Therapeutics Inc. fundamental analysis
No fundamental analysis for Aldeyra Therapeutics Inc. yet.
Aldeyra Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
Aldeyra Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aldeyra Therapeutics Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -39.7M | -48.6M | -34.7M | -56.2M | -62.7M | -42.8M | -60.1M | -35.3M | -18.8M |
| EBITDA | -38.7M | -61.5M | -36.1M | -56.0M | -60.1M | -35.2M | -53.7M | -31.7M | -16.6M |
| Net Income | -38.9M | -49.3M | -37.6M | -57.8M | -62.0M | -37.5M | -55.9M | -33.8M | -17.8M |
| EPS | -1.48 | -1.72 | -0.97 | -0.99 | -1.06 | -0.63 | -0.94 | -0.56 | -0.30 |
| Balance Sheet | |||||||||
| Total Assets | 95.1M | 75.5M | 83.4M | 233M | 181M | 148M | 105M | 72.1M | 47.5M |
| Total Liabilities | 8.47M | 27.4M | 23.8M | 27.4M | 30.3M | 28.5M | 33.6M | 27.8M | 9.66M |
| Shareholders' Equity | 86.6M | 48.1M | 59.5M | 206M | 151M | 120M | 71.0M | 44.3M | 37.9M |
| Cash & Short-term Investments | 47.4M | 44.4M | 77.9M | 230M | 144M | 143M | 54.5M | 70.0M | 45.1M |
| Cash Flow | |||||||||
| Operating Cash Flow | -29.9M | -42.5M | -37.5M | -42.6M | -56.6M | -30.3M | -43.2M | -33.3M | -19.4M |
| Capital Expenditure | 263K | 9.53K | 0.00 | 7.81K | 16.3K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -30.1M | -42.5M | -37.5M | -42.6M | -56.7M | -30.3M | -43.2M | -33.3M | -19.4M |
| Ratios | |||||||||
| ROE | -44.9% | -102.5% | -63.1% | -28.1% | -41.1% | -31.3% | -78.7% | -76.5% | -47.0% |
| ROA | -40.9% | -65.2% | -45.1% | -24.8% | -34.2% | -25.3% | -53.4% | -47.0% | -37.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Aldeyra Therapeutics Inc. dividends
Aldeyra Therapeutics Inc. has not paid dividends in the last 8 fiscal years.
Who owns Aldeyra Therapeutics Inc.
Ownership data of Aldeyra Therapeutics Inc. is not available yet.
Aldeyra Therapeutics Inc. company profile
- Company name
- Aldeyra Therapeutics Inc.
- Ticker
- 137.STU
- Exchange
- Stuttgart Exchange
- Sector
- -
- Industry
- -
- Fiscal year end
- December
- Address
- Website
- -